Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Re-irradiation, and Bevacizumab for Recurrent Glioblastoma
NCT03743662Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2018
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in glioblastoma (GBM) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Survival at 2 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03743662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743662.